This is the authors' abstract. We don't add key points for this paper.
RATIONALE: Hepatocellular carcinoma (HCC) with hepatic vein invasion poses significant treatment challenges and is associated with poor prognosis. Recent studies suggest that a combination of transarterial chemoembolization (TACE), targeted therapy, and immunotherapy may downstage advanced tumors, making surgical resection possible. PATIENT CONCERNS: A 61-year-old female presented with a 3.7 × 3.1 cm hepatic mass invading the hepatic veins. A 75-year-old male exhibited a 6.7 × 5.1 cm liver tumor involving the right hepatic vein. DIAGNOSES: Both patients were diagnosed with advanced HCC with vascular invasion, confirmed by contrast-enhanced imaging and elevated alpha-fetoprotein (AFP) levels. INTERVENTIONS: In case 1, the patient received 2 rounds of TACE and 3 cycles of lenvatinib plus tislelizumab. In case 2, the patient underwent 1 TACE session and 2 cycles of the same combination therapy. Both cases showed significant tumor shrinkage, allowing subsequent R0 surgical resection. OUTCOMES: Pathological evaluation following surgery revealed a major pathological response in both patients. Postoperative recovery was uneventful, and both patients remained disease-free during follow-up. LESSONS: The combination of TACE, lenvatinib, and tislelizumab may offer an effective multimodal strategy for converting unresectable HCC with vascular invasion into resectable disease, potentially improving long-term outcomes.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Qian et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: